See Which Of The Latest 13F Filers Holds MCK

Aggregate 13F data through the 12/31/2025 reporting period shows hedge funds increased their combined McKesson Corp (MCK) holdings by 2,014,523 shares, a roughly 5.21% rise from 38,661,749 to 40,676,272 shares versus 09/30/2025. In the reviewed batch of 40 recent filers, 20 funds held MCK (6 increased positions, 4 decreased, 6 new), with Vanguard Group, MFS and Geode as the top three holders at 12,104,719; 3,446,123; and 2,857,344 shares respectively; note 13F filings report only long positions and omit short exposures.

Analysis

Market structure: The 5.21% aggregate increase (~2.01M shares) in hedge-fund holdings of McKesson (MCK) is a directional but modest demand signal that benefits MCK and, to a lesser extent, peers Cardinal Health (CAH) and AmerisourceBergen (ABC) via sector multiple rerating. Increased institutional ownership (Vanguard, MFS, Geode) raises float stability but can create crowding; expect short-term price support rather than structural valuation change absent earnings/guidance beats.

Risk assessment: Key tail risks are regulatory drug-pricing action (CMS/legislative) that could compress gross margins by 200–400 bps, multi‑$bn legal settlements, or supply-chain shocks; these are low-probability but high-impact over 6–24 months. Immediately (days) flows can buoy price; over weeks–months look to earnings, PBM/retailer contract updates, and litigation updates to shift direction.

Trade implications: Favor idiosyncratic long exposure to MCK sized 2–3% of portfolio using staggered entries (initiate half within 2 weeks, add on ≤5–7% pullback). Use pair trades (long MCK vs short CAH or ABC) to isolate distributor-specific upside and employ options: 90–180 day put-selling or 3–6 month call spreads for defined-risk exposure.

Contrarian angles: The crowd may be underestimating litigation and policy risk—13F data are long-only and hedge funds may be hedged elsewhere—so the ~5% hedge-fund buying is not proof of durable fundamental change. Historical parallels (distributor legal cycles) show rapid reversals; monitor 13F flows, short interest >6%, and CMS announcements as early warning triggers.

Key Decisions for Investors

• Establish a 2–3% net long position in MCK over the next 10 trading days: buy shares or construct a 6‑month 10/0% call spread (buy 10% OTM call, sell 0–5% nearer OTM depending on premium) with a stop-loss at −8% and target take-profit at +12–18% within 3–6 months.
• If willing to be assigned shares, sell 90‑day cash‑secured puts on MCK at strikes ~5–8% below current spot to collect premium; limit exposure to notional 2% of portfolio and only roll once if implied vol falls >20% or premium <0.8% of strike.
• Implement a relative‑value pair: long MCK (2% portfolio) vs short CAH or ABC (1.5%) to neutralize market beta; close or rebalance if the pair spread moves >8% or after 30–90 days around earnings/catalyst events.
• Set explicit risk triggers: reduce MCK exposure by 50% if (a) next quarterly 13F showings drop aggregate hedge‑fund holdings by >3% QoQ, (b) company guidance cites margin hit >200 bps, or (c) new litigation exposure >$1bn is disclosed; reassess within 60 days of any trigger.